ClinicalTrials.gg
CompletedNCT04512066Updated Oct 10, 2023Results posted

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

A Phase 2 interventional study of RO6889450 and Placebo in Schizophrenia, Schizoaffective Disorder, sponsored by Hoffmann-La Roche. Completed at 40 sites in 4 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
9th of 16
287 · median 294
Started
2020
the only one that year
Phase 2
5 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 18th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

03

Conditions studied

  • Schizophrenia, Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 45 years of age inclusive
  • Participants with a , Fifth Edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Disease duration \</=10 years
  • Have a current acute exacerbation of schizophrenia of no more than 8 weeks before screening visit and no current signs of apparent lack of treatment response
  • At the time of screening, the participant needs to be either hospitalized or requiring inpatient psychiatric care according to clinical judgment. If the participant has been hospitalized for the current exacerbation, the hospitalization has to be of a maximum of 1 week prior to screening.
  • In previous exacerbations and hospitalizations, the subject has shown a pattern of response to appropriate antipsychotic treatment
  • Medically stable over a period of 3 months (non-psychiatric conditions) prior to screening visit and not expected to require hospitalization or change of treatment for non-psychiatric conditions for the duration of the study
  • Screening and baseline CGI-S >/=4 (moderate or worse)
  • Screening and baseline PANSS total score >= 80
  • Based on screening and baseline PANSS, scores of >/= 4 (moderate or worse) on 2 or more of the following items: delusions, conceptual disorganization, unusual thought content, hallucinatory behavior, or suspiciousness/persecution
  • between 18 and 35 kg/m2 inclusive
  • Male and female participants; female participants agree to remain abstinent or use acceptable methods during the treatment period and for at least 28 days after the last dose of study drug

Additional inclusion criteria for optional 36-Week Safety Extension Phase

  • Successful completion of the 12-week treatment period
  • No signs or symptoms of worsening of the psychiatric or medical status that would preclude the patient from the participation in the 36-Week Safety Extension Phase or affect their ability to comply with the study requirements.

Exclusion criteria

Exclusion criteria

  • Has been inpatient for > 1 week or had any other hospitalization for acute exacerbation of schizophrenia or schizoaffective disorder within the prior 8 weeks or signs of lack of response to antipsychotic treatment
  • Disease duration > 10 years
  • Is currently an inpatient on an involuntary basis
  • Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) or any suicidal behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS) assessment within one month from screening or between screening and baseline
  • Lifetime history of homicidal behavior
  • Moderate to severe substance use disorder within six months (excluding nicotine) as defined by
  • Other current DSM-5 diagnosis (e.g., bipolar disorder, major depressive disorder)
  • A prior or current general medical condition that might be impairing cognition or other psychiatric functioning (e.g., migraine headaches requiring prophylaxis treatment, head trauma, dementia, seizure disorder, stroke; or neurodegenerative, inflammatory, infectious, neoplastic, toxic, metabolic, or endocrine conditions)
  • abnormalities in laboratory safety test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), including a) (AST), OR alanine aminotransferase (ALT) 2 x (ULN), OR total > 1.5 ULN with the exception of known Gilbert syndrome. b) Serum creatinine > 1.5 ULN
  • Positive result at screening for surface antigen (HBsAg), virus (HCV, untreated), or (HIV)-1 and -2. HCV participants who have been successfully treated and who test negative for HCV RNA are eligible for entry into the study
  • Tardive dyskinesia that is moderate to severe or requires treatment
  • History of neuroleptic malignant syndrome
  • Average triplicate interval greater than 450 msec for males and 470 msec for females or other clinically significant abnormality on screening based on centralized reading
  • Participant for whom risperidone is or who have a documented history of lack of response or intolerance to risperidone or paliperidone or participants with known to risperidone, paliperidone, or to any in Risperdal
  • Participant treated with a long acting injectable antipsychotic or other antipsychotics that cannot be washed-out within the allotted screening period
  • History of electro-convulsive therapy (ECT) for any reason
  • Participant treated with clozapine at any dose within 12 months of screening visit or participants treated with clozapine at 200 mg/day or above at any time; low dose (\< 200mg/day) use for insomnia or dyskinesia longer than 12 months prior to screening visit is permitted
  • Participants currently receiving a psychotropic or other medication used as a psychotropic, which cannot be discontinued during the screening period
  • Positive urine drug screen for amphetamines, methamphetamines, opiates, buprenorphine, methadone, cocaine and barbiturates. In case of positive urine drug screen for cannabinoids, the participant may be allowed to enter the study if approved by Medical Monitor
  • Participant has previously received RO6889450
  • Participant received an drug within 28 days or five times the half-life of the investigational drug prior to the first study drug administration
  • Diagnosis of COVID-19 infection (confirmed or presumptive) 4 weeks prior to screening or during screening. Participants can be re-screened after 4 weeks of full recovery in addition to investigator and/or institutional approval to enroll
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    150 mg Once Daily (QD) RO6889450

    Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.

    Drug: RO6889450

  • Experimental
    45 mg QD RO6889450

    Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.

    Drug: RO6889450

  • Placebo comparator
    Placebo

    Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).

    Drug: Placebo

  • Active comparator
    4 mg QD Risperidone

    Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.

    Drug: Risperidone

Interventions

  • Participants will receive oral RO6889450 QD.

  • DrugPlacebo

    Participants will receive oral placebo QD.

  • Participants will receive oral risperidone QD.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

    The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

    Time frame: Week 4 (Day 28)

Secondary outcomes

  1. Change From Baseline in PANSS Factor Scores at Week 4

    PANSS factors are modified groupings of the 30 PANSS items from the original three subscales (positive, negative, and general psychopathology). Each item is rated on a scale of 1 (absent) to 7 (most extreme). The positive symptom factor contains 8 items (score range 8-56); the negative symptom and disorganized thought/cognition factors contain 7 items (score range 7-49); the uncontrolled hostility/excitement, expressive deficit, and anxiety/depression factors contain 4 items (score range 4-28); and the avolition domain contains 3 items (score range 3-21). The negative and positive totals each have a range of 7-49 and the general total has a range of 16-112. Higher scores indicate higher symptom severity.

    Time frame: Week 4 (Day 28)

  2. Proportion of Participants With at Least 20% or 50% Improvement From Baseline in the PANSS Total Score

    The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

    Time frame: Baseline to Week 12

  3. Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores

    The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.

    Time frame: Week 4 (Day 28)

  4. Clinical Global Impression - Improvement (CGI-I) Scores

    The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.

    Time frame: Week 4 (Day 28)

  5. PANSS Total Score at Week 12

    The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

    Time frame: Week 12

  6. Proportion of Participants With at Least 20% or 50% Improvement in the PANSS Total Score up to Week 12

    The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

    Time frame: Weeks 4, 8, and 12

  7. CGI-S up to Week 12

    The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.

    Time frame: Up to Week 12

  8. CGI-I up to Week 12

    The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.

    Time frame: Up to Week 12

  9. Participants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment

    The RDQ is a tool used to assess inpatients with schizophrenia on their readiness for discharge from inpatient treatment. It consists of five items that assess suicidality/homicidality, control of aggression/impulsivity, activities of daily living, medication-taking, and delusions/hallucinations interfering with functioning and global status. An additional item examines the overall clinical state of the patient and the final question assesses readiness for discharge. The values reported are the proportion (expressed as a percentage) of participants in each analysis group considered ready for discharge according to the RDQ.

    Time frame: after 4-week treatment

  10. Plasma Concentration of RO6889450

    Time frame: Day 7 - Day 336

07

Results

Posted Oct 10, 2023

Participant flow

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestonePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgPlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mg
Started7371697400
Completed5655536000
Not completed1716161400
Withdrew: Adverse event645100
Withdrew: Lack of efficacy335100
Withdrew: Physician decision101000
Withdrew: Withdrawal by subject7951200
Extension Period
Participant flow — Extension Period
MilestonePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgPlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mg
Started04446562526
Completed0302638912
Not completed01420181614
Withdrew: Adverse event014313
Withdrew: Death000001
Withdrew: Lack of efficacy044133
Withdrew: Lost to follow-up015232
Withdrew: Non-compliance with study drug010001
Withdrew: Other020000
Withdrew: Physician decision020110
Withdrew: Withdrawal by subject0371184

Outcome measures

PrimaryMean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4

The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

Time frame:
Week 4 (Day 28)
Reported as:
Mean · Units on a scale
Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
Units on a scalePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Baseline99.38 ± 11.3698.54 ± 9.51100.53 ± 12.25100.03 ± 10.56
Day 2888.69 ± 20.1888.94 ± 17.0385.18 ± 17.6778.04 ± 15.78
Statistical analysis
  • Placebo vs RO6889450 45 mg · Mixed Models Analysis · p = 0.849 · Treatment effect: 0.60 · 90% CI -4.58 to 5.78
  • Placebo vs RO6889450 150 mg · Mixed Models Analysis · p = 0.362 · Treatment effect: -2.83 · 90% CI -7.96 to 2.29
  • Placebo vs Risperidone 4 mg · Mixed Models Analysis · p = 0.001 · Treatment effect: -10.45 · 90% CI -15.46 to -5.43
SecondaryChange From Baseline in PANSS Factor Scores at Week 4

PANSS factors are modified groupings of the 30 PANSS items from the original three subscales (positive, negative, and general psychopathology). Each item is rated on a scale of 1 (absent) to 7 (most extreme). The positive symptom factor contains 8 items (score range 8-56); the negative symptom and disorganized thought/cognition factors contain 7 items (score range 7-49); the uncontrolled hostility/excitement, expressive deficit, and anxiety/depression factors contain 4 items (score range 4-28); and the avolition domain contains 3 items (score range 3-21). The negative and positive totals each have a range of 7-49 and the general total has a range of 16-112. Higher scores indicate higher symptom severity.

Time frame:
Week 4 (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Factor Scores at Week 4
Units on a scalePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Anxiety/Depression - Baseline11.58 ± 3.3912.91 ± 2.9211.54 ± 3.4012.58 ± 3.67
Anxiety/Depression - Day 289.56 ± 4.039.88 ± 4.159.06 ± 4.088.50 ± 4.09
Avolition - Baseline15.99 ± 3.1615.86 ± 2.8316.38 ± 3.2516.20 ± 2.73
Avolition - Day 2814.04 ± 3.7013.67 ± 4.4213.73 ± 3.6912.93 ± 3.44
Disorganized thought/Cognition - Baseline21.86 ± 4.4321.43 ± 4.6622.50 ± 4.8221.45 ± 4.87
Disorganized thought/Cognition - Day 2819.69 ± 6.2520.63 ± 4.9419.41 ± 6.4417.07 ± 4.66
Expressive deficit - Baseline10.89 ± 3.9710.31 ± 3.9610.90 ± 3.7910.23 ± 3.43
Expressive deficit - Day 2810.81 ± 4.0110.69 ± 4.3910.16 ± 4.1810.71 ± 3.67
Totals general - Baseline48.42 ± 6.2448.69 ± 5.4948.68 ± 6.5748.89 ± 6.29
Totals general - Day 2842.43 ± 10.6843.71 ± 9.0640.43 ± 8.9437.07 ± 8.12
Negative symptom factor score - Baseline23.58 ± 5.4423.02 ± 5.1923.81 ± 5.3623.34 ± 4.55
Negative symptom factor score - Day 2821.63 ± 6.0421.27 ± 6.6320.80 ± 5.7020.39 ± 5.55
Totals negative - Baseline24.10 ± 5.2923.65 ± 4.5024.59 ± 4.8723.65 ± 3.78
Totals negative - Day 2822.65 ± 5.8121.82 ± 5.8522.53 ± 5.4121.45 ± 5.13
Positive symptom factor score - Baseline31.40 ± 3.5930.66 ± 3.8432.03 ± 4.8931.15 ± 3.73
Positive symptom factor score - Day 2827.72 ± 7.0328.06 ± 6.1426.63 ± 7.1624.21 ± 5.38
Totals positive - Baseline26.86 ± 3.6026.20 ± 4.1927.26 ± 5.1327.49 ± 3.95
Totals positive - Day 2823.61 ± 6.6423.41 ± 6.1422.22 ± 6.5019.52 ± 5.11
Uncontrolled hostility/excitement - Baseline10.94 ± 3.9410.52 ± 4.0710.65 ± 4.1211.51 ± 3.90
Uncontrolled hostility/excitement - Day 2810.09 ± 4.839.10 ± 4.339.27 ± 4.227.86 ± 4.06
SecondaryProportion of Participants With at Least 20% or 50% Improvement From Baseline in the PANSS Total Score

The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

Time frame:
Baseline to Week 12
Reported as:
Number · Proportion expressed as percentage
Proportion of Participants With at Least 20% or 50% Improvement From Baseline in the PANSS Total Score
Proportion expressed as percentagePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
20% improvement - Week 118.126.227.925.4
20% improvement - Week 226.424.636.843.7
20% improvement - Week 331.932.338.259.2
20% improvement - Week 430.632.336.859.2
50% improvement - Week 101.51.52.8
50% improvement - Week 22.83.14.44.2
50% improvement - Week 32.87.72.914.1
50% improvement - Week 48.37.78.814.1
SecondaryChange From Baseline in Clinical Global Impression Severity (CGI-S) Scores

The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.

Time frame:
Week 4 (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores
Units on a scalePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Baseline5.13 ± 0.505.09 ± 0.525.25 ± 0.635.27 ± 0.61
Day 284.42 ± 1.074.35 ± 0.994.29 ± 0.853.88 ± 0.94
SecondaryClinical Global Impression - Improvement (CGI-I) Scores

The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.

Time frame:
Week 4 (Day 28)
Reported as:
Mean · Units on a scale
Clinical Global Impression - Improvement (CGI-I) Scores
Units on a scalePlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Day 73.87 ± 0.863.60 ± 0.763.56 ± 0.883.40 ± 0.87
Day 143.63 ± 0.943.39 ± 0.953.33 ± 0.902.99 ± 1.01
Day 213.47 ± 1.193.28 ± 1.063.13 ± 1.062.79 ± 1.01
Day 283.27 ± 1.293.27 ± 1.172.96 ± 0.932.43 ± 0.89
SecondaryPANSS Total Score at Week 12

The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
PANSS Total Score at Week 12
Units on a scalePlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Baseline103.44 ± 12.5899.12 ± 10.1698.66 ± 9.6499.00 ± 11.37100.30 ± 11.49
Week 1275.10 ± 17.5376.73 ± 21.0976.25 ± 17.8979.30 ± 13.6867.74 ± 11.50
SecondaryProportion of Participants With at Least 20% or 50% Improvement in the PANSS Total Score up to Week 12

The PANSS is a 30-item rating scale that evaluates positive, negative, and other symptoms in patients with schizophrenia. The Positive subscale is a 7-item scale that assesses features in schizophrenia that are not present in a normal mental state. The Negative subscale is a 7-item scale that assesses features absent in schizophrenia but present in those with a normal mental state. Items are rated on a 7-point scale, where 1 = absent and 7 = extreme, for a maximum score of 49 for each scale. The General subscale is a 16-item scale that assesses the overall severity of schizophrenia and the risk of aggression. Items are rated on the same scale, with a minimum score of 16 and a maximum score of 112. Total scores are calculated by adding subscale scores together, for a minimum score of 30 and a maximum score of 210. Higher scores indicate higher severity.

Time frame:
Weeks 4, 8, and 12
Reported as:
Number · Proportion expressed as a percentage
Proportion of Participants With at Least 20% or 50% Improvement in the PANSS Total Score up to Week 12
Proportion expressed as a percentagePlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Week 440.036.046.353.375.5
Week 836.028.043.937.869.8
Week 1228.028.048.828.950.9
SecondaryCGI-S up to Week 12

The CGI-S measures global severity of illness at a given point in time using a 7-point scale, where 1 = no symptoms and 7 = very severe symptoms.

Time frame:
Up to Week 12
Reported as:
Mean · Units on a scale
CGI-S up to Week 12
Units on a scalePlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Baseline5.28 ± 0.545.16 ± 0.475.05 ± 0.505.16 ± 0.605.26 ± 0.62
Week 123.33 ± 1.003.73 ± 1.273.56 ± 1.013.90 ± 0.853.06 ± 0.81
SecondaryCGI-I up to Week 12

The CGI-I measures change from the baseline state at subsequent visits using a 7-point scale, where 1 = very much improved and 7 = very much worse.

Time frame:
Up to Week 12
Reported as:
Mean · Units on a scale
CGI-I up to Week 12
Units on a scalePlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Day 73.54 ± 0.663.76 ± 0.783.54 ± 0.783.56 ± 0.843.38 ± 0.84
Week 122.33 ± 1.002.73 ± 1.562.30 ± 0.912.65 ± 0.932.00 ± 0.82
SecondaryParticipants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment

The RDQ is a tool used to assess inpatients with schizophrenia on their readiness for discharge from inpatient treatment. It consists of five items that assess suicidality/homicidality, control of aggression/impulsivity, activities of daily living, medication-taking, and delusions/hallucinations interfering with functioning and global status. An additional item examines the overall clinical state of the patient and the final question assesses readiness for discharge. The values reported are the proportion (expressed as a percentage) of participants in each analysis group considered ready for discharge according to the RDQ.

Time frame:
after 4-week treatment
Reported as:
Number · Percentage of participants
Participants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment
Percentage of participantsPlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mg
Participants Ready for Discharge From First Randomized Treatment Intake to Readiness for Discharge as Assessed by the Readiness for Discharge Questionnaire (RDQ) at 4-Week Treatment88.9 (79.3 to 95.1)83.1 (71.7 to 91.2)89.7 (79.9 to 95.8)97.2 (90.2 to 99.7)
SecondaryPlasma Concentration of RO6889450
Time frame:
Day 7 - Day 336
Reported as:
Geometric mean · ng/mL
Plasma Concentration of RO6889450
ng/mLPlacebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mgRO6889450 150 mg
Day 7——99.50 ± 69.2423.83 ± 43.2
Day 14——91.53 ± 111.4463.21 ± 73.6
Day 2849.67 ± 155.4212.27 ± 25.094.57 ± 108.1419.41 ± 93.0
Day 4259.99 ± 248.3274.58 ± 208.8108.57 ± 76.4390.65 ± 138.4
Day 5670.99 ± 320.4217.65 ± 491.6108.59 ± 55.5237.42 ± 541.2
Day 8477.11 ± 85.5165.99 ± 963.092.24 ± 128.5265.09 ± 353.6
Day 168——95.39 ± 46.0733.98 ± 65.5
Day 336——4.13 ± NA139.71 ± 120.6

Adverse events

Collected over 4 weeks for double-blind treatment period Up to 48 weeks for extension period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/72 (0%)1/72 (1.4%)23/72 (31.9%)
RO6889450 45 mg (Double-blind Treatment Period)0/65 (0%)2/65 (3.1%)14/65 (21.5%)
RO6889450 150 mg (Double-blind Treatment Period)0/68 (0%)1/68 (1.5%)23/68 (33.8%)
Risperidone 4 mg (Double-blind Treatment Period)0/71 (0%)0/71 (0%)36/71 (50.7%)
Placebo - RO6889450 45 mg0/25 (0%)3/25 (12%)5/25 (20%)
Placebo - RO6889450 150 mg1/25 (4%)3/25 (12%)6/25 (24%)
RO6889450 45 mg (Extension Period)0/41 (0%)1/41 (2.4%)7/41 (17.1%)
RO6889450 150 mg (Extension Period)0/45 (0%)6/45 (13.3%)12/45 (26.7%)
Risperidone 4 mg (Extension Period)0/53 (0%)1/53 (1.9%)5/53 (9.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboRO6889450 45 mg (Double-blind Treatment Period)RO6889450 150 mg (Double-blind Treatment Period)Risperidone 4 mg (Double-blind Treatment Period)Placebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mg (Extension Period)RO6889450 150 mg (Extension Period)Risperidone 4 mg (Extension Period)
SchizophreniaPsychiatric disorders1/722/650/680/713/252/251/415/450/53
Gun shot woundInjury, poisoning and procedural complications0/720/650/680/710/251/250/410/450/53
AnxietyPsychiatric disorders0/720/650/680/710/250/250/411/450/53
Suicidal ideationPsychiatric disorders0/720/650/680/710/250/250/410/451/53
Psychotic disorderPsychiatric disorders0/720/651/680/710/250/250/410/450/53
Most frequent other events
Most frequent other events
EventPlaceboRO6889450 45 mg (Double-blind Treatment Period)RO6889450 150 mg (Double-blind Treatment Period)Risperidone 4 mg (Double-blind Treatment Period)Placebo - RO6889450 45 mgPlacebo - RO6889450 150 mgRO6889450 45 mg (Extension Period)RO6889450 150 mg (Extension Period)Risperidone 4 mg (Extension Period)
SchizophreniaPsychiatric disorders3/722/650/681/714/253/252/415/450/53
AgitationPsychiatric disorders2/720/658/680/710/251/250/410/450/53
Weight increasedInvestigations1/722/650/688/711/251/250/411/454/53
HeadacheNervous system disorders4/724/655/686/710/250/252/411/451/53
NauseaGastrointestinal disorders4/720/652/686/710/251/251/412/450/53
AnxietyPsychiatric disorders6/723/652/685/710/250/250/411/450/53
InsomniaPsychiatric disorders1/723/655/685/710/250/251/411/450/53
VomitingGastrointestinal disorders2/720/651/685/710/250/251/411/450/53

Baseline characteristics

The efficacy analysis population (EAP) was used to determine baseline characteristics. The EAP included all randomized participants who received at least one dose of study medication and who had primary efficacy assessments at baseline and on at least one occasion post-baseline.

Age, Continuous
Age, Continuous(Years)PlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgTotal
Mean33.2 ± 7.134.0 ± 7.032.3 ± 6.532.9 ± 7.133.1 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgTotal
Female1919151871
Male53465353205
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgTotal
Hispanic or Latino81181037
Not Hispanic or Latino64546061239
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRO6889450 45 mgRO6889450 150 mgRisperidone 4 mgTotal
American Indian or Alaska Native10001
Asian01214
Native Hawaiian or Other Pacific Islander00000
Black or African American33273231123
White37353239143
More than one race01203
Unknown or Not Reported11002
08

Study locations

40 sites
  • Woodland International Research Group Inc.
    Little Rock, Arkansas 72211, United States
  • CITrials, Inc.
    Bellflower, California 90706, United States
  • ProScience Research Group
    Culver City, California 90230, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • California Clinical Trials Medical Group managed by Parexel
    Glendale, California 91206, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • ASCLEPES Research Centers
    Panorama City, California 91402, United States
  • CNRI - Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • CITrials, Inc.
    Riverside, California 92506, United States
  • California Neuropsychopharmacology Clinical Research Institute, LLC
    San Diego, California 92102, United States
  • Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS
    San Diego, California 92103, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Galiz Research, LLC
    Hialeah, Florida 33016, United States
  • Innovative Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • Premier Clinical Research Institute - Miami - BTC - PPDS
    Miami, Florida 33122, United States
  • Research Centers of America - ERG
    Oakland Park, Florida 33334, United States
  • Atlanta Center For Medical Research
    Atlanta, Georgia 30331, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • CBH Health LLC
    Gaithersburg, Maryland 20877, United States
  • Neuro-Behavioral Clinical Research, Inc.
    Canton, Ohio 44718, United States
  • Midwest Clinical Research Center - ERG - PPDS
    Dayton, Ohio 45415, United States
  • Community Clinical Research Inc.
    Austin, Texas 78754, United States
  • Pillar Clinical Research LLC
    Garland, Texas 75042, United States
  • National Center of Neurology and Psychiatry
    Tokyo, 187-8551, Japan
  • Seishinkai Okehazama Hospital Fujita Kokoro Care Center
    Toyoake, 470-1168, Japan
  • Leningradskiy Regional Psychoneurologic Dispensary
    St-Petersburg, Sankt Petersburg 188820, Russian Federation
  • Psychiatry Hospital #1 n.a. P.P.Kashchenko
    St. Petersburg, Sankt Petersburg 188357, Russian Federation
  • Psychiatric Hospital St Nicholas the Wonderworker
    St. Petersburg, Sankt Petersburg 190121, Russian Federation
  • City Psychiatry Hospital #3 n.a. I.I. Skvortsov-Stepanov
    St. Petersburg, Sankt Petersburg 197341, Russian Federation
  • FSBI National Medical Research Centre of Psychiatry and Neurology n.a. V.M. Bekhterev of MoH of RF
    Sankt-peterburg, Vladimir 192019, Russian Federation
  • Saratov regional clinical psychoneurological hospital St Sofii
    Saratov, 410060, Russian Federation
  • Stavropol Regional Psychiatry Hospital #2
    Stavropol, 357034, Russian Federation
  • Tomsk National Scientific Medical Center of Russian Academy of Sciences
    Tomsk, 634009, Russian Federation
  • Communal Non-Commercial Enterprise of Kharkiv RC Regional clinical psychiatric hospital #3
    Kharkiv, Kharkiv Governorate 61068, Ukraine
  • Public NPE Kherson Regional Institution of Mental Care of Kherson RC
    Kherson, Kherson Governorate 73488, Ukraine
  • Kyiv Medical Regional Union Psychiatry
    Kylv, KIEV Governorate 04080, Ukraine
  • Communal Non-Commercial Enterprise Cherkasy Regional Psychiatric Hospital of Cherkasy RC
    Smila, KIEV Governorate 20708, Ukraine
  • Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC
    Vinnytsia, Podolia Governorate 21037, Ukraine
  • Poltava Regional Psychiatry Hospital
    Poltava, Poltava Governorate 36030, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jun 2022, 21 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 21 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2020
First posted
Aug 13, 2020
StartActual
Sep 8, 2020
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Results first posted
Oct 10, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04512066
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 13, 2020
Start date
Sep 8, 2020
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Results posted
Oct 10, 2023
Last update
Oct 10, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ralmitaront

Start the discussion